Novo Nordisk A/S (NVO)
| Market Cap | 176.42B -35.6% |
| Revenue (ttm) | 50.34B +5.6% |
| Net Income | 17.79B +4.8% |
| EPS | 4.00 +5.0% |
| Shares Out | 4.43B |
| PE Ratio | 9.91 |
| Forward PE | 12.30 |
| Dividend | $1.28 (3.24%) |
| Ex-Dividend Date | Aug 17, 2026 |
| Volume | 12,817,382 |
| Open | 39.50 |
| Previous Close | 39.80 |
| Day's Range | 39.11 - 39.89 |
| 52-Week Range | 35.12 - 64.16 |
| Beta | 0.34 |
| Analysts | Hold |
| Price Target | 46.80 (+18.27%) |
| Earnings Date | Nov 4, 2026 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for NVO stock is "Hold." The 12-month stock price target is $46.8, which is an increase of 18.27% from the latest price.
News
Novo CEO says pills could capture 50% of weight-loss market by 2030
Weight-loss pills could capture as much as half of the global obesity drug market by 2030, Novo Nordisk's chief executive told Reuters on Tuesday, as the Danish drugmaker positions itself for a shif...
Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire.
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk's market duopoly.
Novo Nordisk and UNICEF renew push to prevent childhood obesity
Novo Nordisk and UNICEF have expanded their partnership to help prevent childhood overweight and obesity, the Danish drugmaker said on Tuesday.
Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy?
The molecule, the active ingredient in both Wegovy and Ozempic, powered the company to unprecedented success. With that, however, investor expectations are high, and it's not hard for those folks to b...
Novo CEO says company needs to increase investor confidence, Bloomberg says
Novo Nordisk (NVO) CEO Mike Doustdar said the company has to do more to increase investor confidence as it faces patent expiration in the U.S. and Europe for Ozempic and…
Novo CEO on M&A: Let's see where the gaps are
Novo CEO Mike Doustdar tells CNBC the drugmaker is mulling M&A opportunities amid increasing competition, and details how the company's units in China and North America are performing.
Novo Stock (NVO): Deutsche Bank Keeps Sell Rating, Says Growth Strategy ‘Underwhelming on Multiple Fronts’
Novo shares fell 7.96% to $39.80 on Monday after its growth strategy, disclosed at its Capital Markets Day in London, failed to impress investors In response, Deutsche Bank maintained its Buy rating o...
Novo CEO signals M&A opportunities to strengthen drug pipeline
Novo CEO Mike Doustdar told CNBC it's mulling M&A opportunities amid increasing competition. In this article NVO
Novo Still Has Work to Do to Build Investor Confidence, CEO Says
Novo CEO Mike Doustdar discusses investor confidence, drug testing and the potential for expanding the firm's obesity offerings. "We should also have a mindset that we don't have a patent or a monopol...
Is Novo Nordisk AS (NVO) a Bargain After 8.0% Drop? GF Value Says Undervalued
Is Novo Nordisk AS (NVO) a Bargain After 8.0% Drop? GF Value Says Undervalued
Novo Nordisk is a value trap, says UBS' Michael Yee
Michael Yee, UBS senior pharma and biotech analyst, joins 'Fast Money' to share his take on the top players in the obesity drug market.
Monday's Final Takeaways: NVO Stumbles in GLP-1 Race, U.S.-China Summit Begins
Eli Lilly (LLY) is gaining speed in capturing the GLP-1 craze as Novo (NVO) continues to struggle in catching a bullish bid. Meanwhile, the U.S.-China summit begins with President Trump and China Pres...
Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction
Novo Nordisk A/S NYSE: NVO outlined an updated strategy at its Capital Markets Day centered on diabetes and obesity, expansion into blood and endocrine disorders, liver disease and cardiovascular cond...
Novo Nordisk Faces Challenges Amid Capital Markets Day Insights
Novo Nordisk Faces Challenges Amid Capital Markets Day Insights
Why Novo Nordisk Stock Just Crashed
Novo Nordisk plans to unveil 5 big new drugs in 5 years. Novo will also grow sales by $23 billion in 10 years.
Novo Nordisk (NVO) Cuts Jobs Amid Competitive Pressure and Plans New Drug Launches
Novo Nordisk (NVO) Cuts Jobs Amid Competitive Pressure and Plans New Drug Launches
Eli Lilly Stock (LLY) Rises as Novo’s Growth Strategy Fails to Impress Wall Street
Shares of Eli Lilly ($LLY) are trending higher after rival Novo ($NVO) outlined a new growth strategy that failed to impress investors or analysts.
Novo Stock (NVO) Drops 5% Despite Beating Eli Lilly in New CagriSema Trial After Earlier Failure
Shares in Danish obesity drugmaker Novo ($NVO) fell by 5% to around $41 early Monday, despite the company’s success in its late-stage Reimagine 5 trial. The study compared its next-generation…
Wegovy-maker Novo shares slump as management grilled on pricing, M&A
Novo Nordisk shares slid as much as 9 per cent on Monday as executives faced tough questions from analysts over the drugmaker’s pricing power and dealmaking strategy ahead of looming patent expiries.
First Look: US Futures Rise, Bitcoin Hits $85K, Novo Nordisk Drops
First Look: US Futures Rise, Bitcoin Hits $85K, Novo Nordisk Drops
Novo Nordisk's $23B Obesity Goal Isn't Enough to Stop the Selloff
Novo Nordisk's $23B Obesity Goal Isn't Enough to Stop the Selloff
Why Novo Stock Is Dropping After Drugmaker Unveils Ambitious Growth Plan
Novo Nordisk plans to launch at least five multi-blockbuster drugs by 2030 and is targeting pipeline drug sales of $23 billion by 2035.
Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers
Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers
Novo says its next-gen obesity drug tops Lilly rival in late-stage study
Novo Nordisk said on Monday its next-generation experimental drug had achieved an estimated average weight loss of 12.4% in a late-stage trial and that it was superior to Eli Lilly's d...